Mono Pharmacare financials and balance sheet

NSE: MONOPHARMAPharmaceuticals & Biotechnology

Last close ₹8.50down ₹0.40 (4.49%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹8.90.

52-week range of traded prices to 23 Oct 2026
₹7.50Low, 10 Aug 2026₹22.05High, 28 Nov 2025
Market cap
₹15 Cr
P/E
42.4
P/B
0.5
Dividend yield
Nonein the last 12 months
ROE
1.1%
Debt to equity
1.79
Volume, NSE
2,000100.0% delivered

3 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Mono Pharmacare annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹168 Cr, year to Mar 2025

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue166
  2. Materials and goods−157
  3. Employee costs−3.8
  4. Other expenses−1.1
  5. Operating profit4.0
  6. Depreciation−0.1
  7. Other income0.0
  8. Finance costs−3.3
  9. Profit before tax0.6
  10. Tax−0.2
  11. Net profit0.4

What the company owns

  • Receivables₹75 Cr
  • Inventory₹42 Cr
  • Plant, investments and other assets₹4 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Borrowings₹57 Cr
  • Net worth₹32 Cr
  • Owed to suppliers₹29 Cr
  • Other liabilities₹5 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Mono Pharmacare half-yearly results

₹ croreMar 2024Mar 2025Filed 31 MayMar 2026Filed 16 Jul
Revenue from operations122168166
116161162
Materials and goods bought111152157
Employee costs444
Other expenses251
Operating profit before depreciation684
Operating margin5.2%4.5%2.4%
Materials, % of revenue90.5%90.5%94.7%
Employee costs, % of revenue2.9%2.2%2.3%
Other expenses, % of revenue1.5%2.7%0.7%
Depreciation and amortisation000
Operating profit after depreciation684
Other income010
Finance costs343
One-off items0––
Profit before tax341
110
Net profit230
Net margin2.0%1.8%0.2%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Filed 31 MayMar 2026Filed 16 Jul
3132
3132
Share capital1818
Reserves1414
Belonging to outside owners of subsidiaries00
5457
5363
2627
Total assets110122
11
109121
Net debt5356
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Filed 31 MayMar 2026Filed 16 Jul
−4.32.3
−2.92.6
−11.5−1.5
Receivables−10.3−33.0
Inventories−13.113.0
Payables9.110.4
Other working capital2.78.2
Tax paid−1.4−0.3
Capital spending0.20.0
Free cash flow−4.52.3
Cash from investing−0.20.0
4.9−2.0
Dividends paid0.00.0
Shares issued0.00.0
Net change in cash0.30.3
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2024.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2024Mar 2025Filed 31 MayMar 2026Filed 16 Jul
Earnings per share–₹1.75₹0.20
Diluted earnings per share–₹1.75₹0.20
Book value per share–₹17.66₹17.86
Shareholder yield–0.0%0.0%
Market cap at the year end (₹ crore)77.940.819.7

Ratios

Consolidated, years to March.Mono Pharmacare PE ratio and valuation

RatioMar 2024Mar 2025Filed 31 MayMar 2026Filed 16 Jul
Revenue growth–37.6%−1.6%
Operating profit growth–20.7%−47.7%
Net profit growth–26.5%−88.6%
Earnings per share growth––−88.6%
–9.9%1.1%
––−8.8 pts
From the net margin––−8.8 pts
From asset turnover––−0.1 pts
From borrowing––0.1 pts
Return on capital employed–8.9%4.4%
Cash conversion–−139.2%650.9%
Interest cover2.01.91.2
Debt to equity–1.711.79
Receivable days–91165
Inventory days–13399
Payable days–4568
Cash conversion cycle, days–178196
Working capital days–180190
Asset turnover–1.531.43
Assets per rupee of net worth–3.533.70
Sales per rupee of plant–171.41189.25
Capital spending to depreciation–1.760.04
No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
0.3%
Cash from operations against operating profit
57.5%
Measure3 years
Return on equity, average5.5%
Return on capital employed, average6.6%
Operating margin, average4.0%
Net margin, average1.3%
Asset turnover, average1.48
Cash conversion cycle, days, average187
Interest cover, average1.7
Debt to equity, average1.75

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations2.30
Cash from investing0.00
Cash from financing−2.01
Capital spending0.00
Dividends paid0.00
Shares issued for cash0.00
Borrowings raised1.27
Borrowings repaid0.00

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points––80.47
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––−26.37
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––−4.87
Effective tax ratePublished threshold 17.16 per cent23.7830.4138.78
Tax charged less tax paid, % of profitOur threshold 10 percentage points–−0.74−5.73
A threshold marked as ours has no published figure; it is the line we read the check against.